Small improvement seen in global cognition scores, but no different from those following control diet with mild caloric restriction<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, July 19, 2023 (HealthDay News) — The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) with mild caloric restriction does not change cognition or brain magnetic resonance imaging (MRI) outcomes compared with a control diet with mild caloric restriction, according to a study published online July 18 in the New England Journal of Medicine<\/em> to coincide with the annual Alzheimer’s Association International Conference, held from July 16 to 20 in Amsterdam.<\/p>\n Lisa L. Barnes, Ph.D., from the Rush Alzheimer’s Disease Center in Chicago, and colleagues performed a two-site randomized controlled trial involving older adults without cognitive impairment with a family history of dementia, a body mass index greater than 25 kg\/m2<\/sup>, and a suboptimal diet to examine the cognitive effects of the MIND diet with mild caloric restriction compared with a control diet with mild caloric restriction (301 and 303 participants, respectively). To promote weight loss, all participants received counseling regarding adherence to their assigned diet plus support.<\/p>\n The researchers found that from baseline to year 3, both groups had improvements in global cognition scores, with increases of 0.205 and 0.170 standardized units in the MIND- and control-diet groups, respectively. The two groups had similar changes in white-matter hyperintensities, hippocampal volumes, and total gray- and white-matter volumes on MRI.<\/p>\n “Participants who followed the MIND diet had small improvements in a global measure of cognition that were similar to those who followed a control diet with mild caloric restriction,” the authors write.<\/p>\n Two authors disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n